What is the serious side effect linked to Ozempic and similar weight-loss drugs?

The serious side effect linked to Ozempic and similar weight-loss drugs is blindness, often due to a condition called non-arteritic anterior ischemic optic neuropathy (NAION).

How are weight-loss drugs like Ozempic associated with vision loss?

Weight-loss drugs like Ozempic are associated with vision loss because they may cause inflammation and block blood flow to the eye, potentially damaging blood vessels.

Are there any potential treatments for vision loss caused by weight-loss drugs?

Yes, researchers are working on anti-aging treatments that have shown potential in animal studies to restore vision in cases of blindness caused by these weight-loss drugs.

Home / Health / Expert Warns of 'Eye Stroke' from Ozempic

Expert Warns of 'Eye Stroke' from Ozempic

5 Feb

•

Summary

New warnings highlight blindness as a side effect of weight-loss drugs.
Studies link semaglutide and tirzepatide to vision loss conditions like NAION.
Researchers are exploring anti-aging treatments to potentially restore vision.

Expert Warns of 'Eye Stroke' from Ozempic

A significant health warning has been issued concerning a life-altering side effect of weight-loss drugs, including Ozempic, that can lead to blindness. Several studies have established a connection between these medications and conditions causing eye inflammation and impaired blood flow, resulting in severe and potentially permanent vision loss.

The drugs, specifically semaglutide and tirzepatide, active ingredients in Ozempic and Mounjaro respectively, were first linked to a rare, irreversible eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION) in 2024. Reports detailed instances where patients experienced sudden blindness following the administration of these drugs.

Experts are exploring the exact cause, with theories suggesting that rapid blood sugar reduction by these drugs may damage delicate eye blood vessels. While the risk is considered very small, estimated at about one in 10,000 GLP-1 patients, health authorities are urging vigilance. Patients experiencing sudden vision changes are advised to seek immediate medical attention.